Drug intelligence / Profile preview

PLJT-004

Development stage: Preclinical
Lead developer: Panlong Pharmaceutical

Overview

PLJT-004 is an **improved traditional Chinese medicine** candidate being developed by Panlong Pharma for **orthopedic pain**. It is reported to be in preclinical research. Public disclosures do not specify its herbal composition, molecular targets, pharmacologic mechanism, dosage form, or route of administration.

Beyond the preview

Go deeper on PLJT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLJT-004.

Explore the full profile